NEW YORK (GenomeWeb News) – Singapore-based VolitionRx today announced it has raised about $1.2 million, which will be used to support further development of its diagnostic test kits.

The firm, which is developing blood-based diagnostic tests for cancer using its nucleosomes technology, raised about $1 million through a private placement of 582,510 shares for $1.75 per share. Each share entitles the holder to one share of common stock and one warrant to purchase half a share of common stock at $2.60 per share, valid for four years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.